Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Ipsen price target raised to EUR 72 from EUR 62 at Barclays » 14:18
06/01/20
06/01
14:18
06/01/20
14:18
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

Barclays analyst Emily…

Barclays analyst Emily Field raised the firm's price target on Ipsen to EUR 72 from EUR 62 and keeps an Equal Weight rating on the shares.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

06/01/20 BofA
Ipsen upgraded to Buy from Neutral at BofA
05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
05/18/20 JPMorgan
Ipsen upgraded to Neutral from Underweight at JPMorgan
04/23/20 Oddo BHF
Ipsen upgraded to Buy from Neutral at Oddo BHF
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Upgrade
Ipsen upgraded to Buy from Neutral at BofA » 05:42
06/01/20
06/01
05:42
06/01/20
05:42
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

BofA upgraded Ipsen to…

BofA upgraded Ipsen to Buy from Neutral with a EUR 90 price target.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

05/18/20 JPMorgan
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan
05/18/20 JPMorgan
Ipsen upgraded to Neutral from Underweight at JPMorgan
04/23/20 Oddo BHF
Ipsen upgraded to Buy from Neutral at Oddo BHF
04/22/20 UBS
Ipsen price target raised to EUR 99 from EUR 90 at UBS
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Friday
Recommendations
Immunomedics' sacituzumab activity remains consistent, says Piper Sandler » 13:51
05/29/20
05/29
13:51
05/29/20
13:51
IMMU

Immunomedics

$32.81 /

-0.45 (-1.35%)

Piper Sandler analyst…

Piper Sandler analyst Joseph Catanzaro reiterated an Overweight rating and $40 price target on Immunomedics after the company presented initial data from two sacituzumab cohorts in bladder and endometrial cancer. The analyst said that "most notable" is the bladder data from Cohort 2 of TROPHY-U-01 in post-CPI platinum-ineligible disease which showed a 29% overall response rate in 21 patients, identical to the 29% ORR observed so far in the post-chemo/CPI Cohort 1. Catanzaro believes that if this response rate is maintained over a bigger cohort it should be supportive of an accelerated sBLA submission in this setting.

ShowHide Related Items >><<
IMMU Immunomedics
$32.81 /

-0.45 (-1.35%)

IMMU Immunomedics
$32.81 /

-0.45 (-1.35%)

05/28/20 H.C. Wainwright
Immunomedics CEO change to not impact Trodelvy launch, says H.C. Wainwright
05/28/20 Piper Sandler
Immunomedics confident in execution despite CEO change, says Piper Sandler
05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
IMMU Immunomedics
$32.81 /

-0.45 (-1.35%)

IMMU Immunomedics
$32.81 /

-0.45 (-1.35%)

IMMU Immunomedics
$32.81 /

-0.45 (-1.35%)

IMMU Immunomedics
$32.81 /

-0.45 (-1.35%)

Thursday
Recommendations
Immunomedics CEO change to not impact Trodelvy launch, says H.C. Wainwright » 07:06
05/28/20
05/28
07:06
05/28/20
07:06
IMMU

Immunomedics

$34.18 /

+0.1 (+0.29%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Raghuram Selvaraju does not believe the departure of Immunomedics CEO Harout Semerjian should impact Trodelvy's potential for commercial success. The company's virtual interactions with physicians, coupled with the superior efficacy profile of Trodelvy relative to chemotherapy, should drive "healthy" market penetration near-term, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on Immunomedics with a $54 price target.

ShowHide Related Items >><<
IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

05/28/20 Piper Sandler
Immunomedics confident in execution despite CEO change, says Piper Sandler
05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

Recommendations
Immunomedics confident in execution despite CEO change, says Piper Sandler » 05:01
05/28/20
05/28
05:01
05/28/20
05:01
IMMU

Immunomedics

$34.18 /

+0.1 (+0.29%)

After speaking to the…

After speaking to the company, Piper Sandler analyst Joseph Catanzaro says Immunomedics remains confident in its near term execution, namely the Trodelvy commercial launch. The COVID environment created a "logistical nightmare" for former CEO Harout Semerjian, who needed to ramp quickly during a period critical to the company's growth and long term success, Catanzaro tells investors in a research note. The analyst keeps an Overweight rating on Immunomedics with a $40 price target.

ShowHide Related Items >><<
IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
04/24/20
Fly Intel: Top five analyst upgrades
IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

Wednesday
On The Fly
Fly Intel: After-Hours Movers » 19:08
05/27/20
05/27
19:08
05/27/20
19:08
NTNX

Nutanix

$24.94 /

+0.53 (+2.17%)

, COHR

Coherent

$149.11 /

+3.8 (+2.62%)

, HPQ

HP Inc.

$17.13 /

+0.06 (+0.35%)

, NTAP

NetApp

$46.30 /

+1.23 (+2.73%)

, ADSK

Autodesk

$199.71 /

+0.28 (+0.14%)

, HTZ

Hertz

$1.31 /

+0.7199 (+122.00%)

, IOVA

Iovance Biotherapeutics

$38.12 /

+0.66 (+1.76%)

, ARNA

Arena Pharmaceuticals

$58.07 /

+1.16 (+2.04%)

, CRNC

Cerence

$33.05 /

+0.47 (+1.44%)

, BCRX

BioCryst

$5.03 /

-0.17 (-3.27%)

, IMMU

Immunomedics

$34.18 /

+0.1 (+0.29%)

, PEN

Penumbra

$170.74 /

+1.29 (+0.76%)

, TWTR

Twitter

$33.06 /

-0.96 (-2.82%)

, PLT

Plantronics

$14.66 /

+0.67 (+4.79%)

, IMAB

I-MAB

$23.87 /

+0.665 (+2.87%)

, BA

Boeing

$149.46 /

+4.77 (+3.30%)

, HPP

Hudson Pacific

$24.18 /

+1.06 (+4.59%)

, DHC

Diversified Healthcare Trust

$3.23 /

+0.03 (+0.94%)

, PLMR

Palomar

$65.68 /

+2.57 (+4.07%)

, PHAS

PhaseBio

$4.42 /

-0.03 (-0.67%)

, SPTN

SpartanNash

$20.57 /

-0.02 (-0.10%)

, WDAY

Workday

$170.10 /

+1.72 (+1.02%)

, TOL

Toll Brothers

$32.95 /

+2.835 (+9.42%)

, BGFV

Big 5 Sporting

$1.94 /

+0.06 (+3.19%)

, SMTC

Semtech

$50.13 /

+1.18 (+2.41%)

Check out this evening's…

Open Full Text

ShowHide Related Items >><<
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

COHR Coherent
$149.11 /

+3.8 (+2.62%)

BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

05/21/20 JPMorgan
Nutanix price target lowered to $24 from $27 at JPMorgan
05/19/20 OTR Global
Nutanix downgraded to Mixed from Positive at OTR Global
04/27/20 Needham
Nutanix price target lowered to $24 from $42 at Needham
04/23/20 Cleveland Research
Nutanix trends in April softened versus prior months, says Cleveland Research
COHR Coherent
$149.11 /

+3.8 (+2.62%)

04/23/20 Goldman Sachs
Coherent upgraded to Buy from Neutral at Goldman Sachs
02/10/20
Fly Intel: Top five analyst initiations
02/10/20 Stifel
Coherent transferred with a Buy, $178 price target at Stifel
02/06/20 Piper Sandler
Coherent price target lowered to $195 from $205 at Piper Sandler
HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

05/26/20 Credit Suisse
HP Inc. price target lowered to $17 from $22 at Credit Suisse
05/22/20 JPMorgan
HP shares worth owning through downturn, says JPMorgan
04/27/20 Loop Capital
Xerox, Park City, NetApp, HP Enterprise cut to Hold from Buy at Loop Capital
04/21/20 Deutsche Bank
HP Inc. price target lowered to $17 from $20 at Deutsche Bank
NTAP NetApp
$46.30 /

+1.23 (+2.73%)

05/19/20 Barclays
Barclays lowers estimates in IT hardware after April survey
05/11/20
Fly Intel: Top five analyst downgrades
05/11/20 Stifel
NetApp downgraded to Hold from Buy at Stifel
ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

05/22/20 Deutsche Bank
Autodesk price target lowered to $215 from $230 at Deutsche Bank
05/21/20 Citi
Citi sees difficult setup for Autodesk into results, cuts price target
05/19/20 KeyBanc
Autodesk price target raised to $210 from $200 at KeyBanc
05/07/20 OTR Global
Autodesk downgraded to Mixed from Positive at OTR Global
HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

05/05/20 Morgan Stanley
2020 may not be quite as bad as feared for used cars, says Morgan Stanley
04/27/20
Fly Intel: Top five analyst downgrades
04/27/20 Barclays
Barclays downgrades Hertz to Underweight on risk of capital call
04/27/20 Barclays
Hertz downgraded to Underweight from Equal Weight at Barclays
IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

04/29/20 Oppenheimer
Iovance Biotherapeutics price target raised to $43 from $35 at Oppenheimer
04/29/20 H.C. Wainwright
Iovance Biotherapeutics price target raised to $48 from $36 at H.C. Wainwright
04/27/20 Piper Sandler
AACR abstract for Moffitt study positive for Iovance, says Piper Sandler
04/22/20 Piper Sandler
AACR meeting should bring more support for Iovance TILs, says Piper Sandler
ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

05/18/20
Fly Intel: Top five analyst initiations
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
05/18/20 Jefferies
Arena Pharmaceuticals initiated with a Buy at Jefferies
03/31/20 Guggenheim
Guggenheim starts Arena at Buy on 'pipeline-in-a-product' etrasimod
CRNC Cerence
$33.05 /

+0.47 (+1.44%)

05/27/20 Wedbush
Cerence price target raised to $40 from $27 at Wedbush
05/26/20 Raymond James
Cerence downgraded to Outperform from Strong Buy at Raymond James
05/26/20 Raymond James
Cerence downgraded to Outperform from Strong Buy at Raymond James
05/12/20
Fly Intel: Top five analyst initiations
BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

05/06/20 JMP Securities
BioCryst has potential best-in-class PNH treatment, says JMP Securities
05/06/20 Piper Sandler
BioCryst price target raised to $10 from $8 at Piper Sandler
05/05/20 Barclays
BioCryst upgraded to Overweight from Equal Weight at Barclays
04/29/20 JMP Securities
Positive remdesivir news 'bodes well' for BioCryst, says JMP Securities
IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
04/24/20
Fly Intel: Top five analyst upgrades
PEN Penumbra
$170.74 /

+1.29 (+0.76%)

05/08/20 Citi
Penumbra price target raised to $214 from $192 at Citi
03/04/20 Citi
Penumbra initiated with a Buy at Citi
03/02/20 Wells Fargo
Baxter, J&J best positioned to weather coronavirus spread, says Wells Fargo
02/26/20 Canaccord
Penumbra weakness buying opportunity, says Canaccord
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

05/27/20 Cowen
Cowen says Twitter 'will be fine,' but Republicans could support Facebook suit
05/06/20 China Renaissance
Twitter price target lowered to $23 from $25 at China Renaissance
05/01/20
Fly Intel: Top five analyst downgrades
05/01/20 Deutsche Bank
Twitter price target raised to $28 from $22 at Deutsche Bank
PLT Plantronics
$14.66 /

+0.67 (+4.79%)

04/16/20 Morgan Stanley
Morgan Stanley cuts Plantronics to Underweight citing upcoming challenges
04/16/20 Morgan Stanley
Plantronics downgraded to Underweight from Equal Weight at Morgan Stanley
03/30/20 JPMorgan
Plantronics downgraded to Underweight from Neutral at JPMorgan
03/30/20 JPMorgan
Plantronics downgraded to Underweight from Neutral at JPMorgan
IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

02/14/20
Fly Intel: Top five analyst initiations
02/13/20 CICC
I-MAB initiated with an Outperform at CICC
02/12/20
Fly Intel: Top five analyst initiations
02/11/20 China Renaissance
I-MAB initiated with a Buy at China Renaissance
BA Boeing
$149.46 /

+4.77 (+3.30%)

05/22/20 Canaccord
Boeing price target lowered to $155 from $175 at Canaccord
05/20/20 RBC Capital
RBC starts Boeing at Outperform on favorable risk/reward profile
05/20/20 RBC Capital
Boeing initiated with an Outperform at RBC Capital
05/05/20 Nord/LB
Boeing downgraded to Sell from Hold at Nord/LB
HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

04/16/20 Jefferies
Hudson Pacific initiated with a Hold at Jefferies
02/04/20 Mizuho
Hudson Pacific assumed with a Buy at Mizuho
01/15/20 Mizuho
Hudson Pacific upgraded to Buy from Neutral at Mizuho
11/08/19 Goldman Sachs
Hudson Pacific initiated with a Buy at Goldman Sachs
DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

05/19/20 RBC Capital
Diversified Healthcare Trust price target lowered to $3 from $7 at RBC Capital
03/11/20 Mizuho
Sabra Health Care to be pressured by coronavirus at facility, says Mizuho
01/16/20 Wells Fargo
Diversified Healthcare Trust cut to Equal Weight from Overweight at Wells Fargo
01/07/20 Raymond James
Healthcare REIT sector downgraded to Market Weight at Raymond James
PLMR Palomar
$65.68 /

+2.57 (+4.07%)

01/14/20 JMP Securities
Palomar price target raised to $55 from $50 at JMP Securities
01/10/20 Keefe Bruyette
Palomar target raised to $58 after share offering at Keefe Bruyette
12/16/19 William Blair
Palomar should be bought despite recent rally, says William Blair
12/08/19 Keefe Bruyette
Palomar price target raised to $57 from $48 at Keefe Bruyette
PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

05/07/20 Stifel
Portola deal highlights value of PhaseBio's PB2452, says Stifel
04/06/20 Citi
PhaseBio price target lowered to $11 from $25 at Citi
01/27/20 William Blair
PhaseBio could see increase to PB2452 addressable market, says William Blair
01/16/20 Stifel
PhaseBio acquisition of PB6440 an 'excellent' strategic move, says Stifel
SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

03/19/20 Barclays
SpartanNash upgraded to Equal Weight from Underweight at Barclays
03/18/20 BMO Capital
SpartanNash upgraded to Market Perform from Underperform at BMO Capital
10/04/19
SpartanNash management to meet with Loop Capital
WDAY Workday
$170.10 /

+1.72 (+1.02%)

05/21/20 OTR Global
Workday downgraded to Mixed from Positive at OTR Global
05/18/20
Fly Intel: Top five analyst downgrades
05/18/20 Cleveland Research
Workday downgraded to Neutral from Buy at Cleveland Research
05/18/20 RBC Capital
Workday price target lowered to $194 from $230 at RBC Capital
TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

05/27/20 Credit Suisse
Toll Brothers initiated with a Neutral at Credit Suisse
05/27/20 Credit Suisse
KB Home initiated with an Outperform at Credit Suisse
05/11/20 Wedbush
Toll Brothers price target lowered to $35 from $48 at Wedbush
05/04/20 Evercore ISI
Toll Brothers upgraded to In Line from Underperform at Evercore ISI
BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

03/12/20 Susquehanna
Semtech results inline and guidance better than feared, says Susquehanna
03/12/20 Loop Capital
Semtech price target lowered to $46 from $56 at Loop Capital
03/12/20 B. Riley FBR
Semtech price target lowered to $50 from $55 at B. Riley FBR
03/12/20 Needham
Semtech upgraded to Buy from Hold at Needham
WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

SPTN SpartanNash
$20.57 /

-0.02 (-0.10%)

SMTC Semtech
$50.13 /

+1.18 (+2.41%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

COHR Coherent
$149.11 /

+3.8 (+2.62%)

BGFV Big 5 Sporting
$1.94 /

+0.06 (+3.19%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

  • 29
    May
  • 28
    May
  • 28
    May
  • 28
    May
TWTR Twitter
$33.06 /

-0.96 (-2.82%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

HPP Hudson Pacific
$24.18 /

+1.06 (+4.59%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PLMR Palomar
$65.68 /

+2.57 (+4.07%)

PEN Penumbra
$170.74 /

+1.29 (+0.76%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

IMAB I-MAB
$23.87 /

+0.665 (+2.87%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

CRNC Cerence
$33.05 /

+0.47 (+1.44%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ARNA Arena Pharmaceuticals
$58.07 /

+1.16 (+2.04%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

WDAY Workday
$170.10 /

+1.72 (+1.02%)

TWTR Twitter
$33.06 /

-0.96 (-2.82%)

TOL Toll Brothers
$32.95 /

+2.835 (+9.42%)

PLT Plantronics
$14.66 /

+0.67 (+4.79%)

PHAS PhaseBio
$4.42 /

-0.03 (-0.67%)

NTNX Nutanix
$24.94 /

+0.53 (+2.17%)

NTAP NetApp
$46.30 /

+1.23 (+2.73%)

IOVA Iovance Biotherapeutics
$38.12 /

+0.66 (+1.76%)

IMMU Immunomedics
$34.18 /

+0.1 (+0.29%)

HTZ Hertz
$1.31 /

+0.7199 (+122.00%)

HPQ HP Inc.
$17.13 /

+0.06 (+0.35%)

DHC Diversified Healthcare Trust
$3.23 /

+0.03 (+0.94%)

BCRX BioCryst
$5.03 /

-0.17 (-3.27%)

BA Boeing
$149.46 /

+4.77 (+3.30%)

ADSK Autodesk
$199.71 /

+0.28 (+0.14%)

Hot Stocks
Immunomedics drops 5% to $32.48 after CEO steps down  16:13
05/27/20
05/27
16:13
05/27/20
16:13
IMMU

Immunomedics

$34.16 /

+0.08 (+0.23%)

 
ShowHide Related Items >><<
IMMU Immunomedics
$34.16 /

+0.08 (+0.23%)

IMMU Immunomedics
$34.16 /

+0.08 (+0.23%)

05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
04/24/20
Fly Intel: Top five analyst upgrades
IMMU Immunomedics
$34.16 /

+0.08 (+0.23%)

IMMU Immunomedics
$34.16 /

+0.08 (+0.23%)

IMMU Immunomedics
$34.16 /

+0.08 (+0.23%)

IMMU Immunomedics
$34.16 /

+0.08 (+0.23%)

Hot Stocks
Immunomedics says TROPiCS-02 patient enrollment resumed at 20 sites » 16:12
05/27/20
05/27
16:12
05/27/20
16:12
IMMU

Immunomedics

$34.17 /

+0.09 (+0.26%)

Immunomedics announced…

Immunomedics announced that patient enrollment into the Phase 3 TROPiCS-02 study of Trodelvy in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer, has been resumed at approximately 20 clinical sites as of mid-May, with additional sites continuing to open in the coming weeks. The company's commercial organization is responding to the challenges presented by COVID-19, and early feedback remains encouraging, it added. Further, "manufacturing continues to operate at capacity across the global supply chain, with minimal COVID-19 impact," it said. Immunomedics noted that previously communicated updates remain on track, with the ASCENT topline readout expected in mid-2020, and topline data from the first full cohort of 100 metastatic urothelial cancer patients with prior platinum-based and checkpoint inhibitor therapies in the TROPHY U-01 study targeted to be presented at a medical conference in the second half of 2020.

ShowHide Related Items >><<
IMMU Immunomedics
$34.17 /

+0.09 (+0.26%)

IMMU Immunomedics
$34.17 /

+0.09 (+0.26%)

05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
04/24/20
Fly Intel: Top five analyst upgrades
IMMU Immunomedics
$34.17 /

+0.09 (+0.26%)

IMMU Immunomedics
$34.17 /

+0.09 (+0.26%)

IMMU Immunomedics
$34.17 /

+0.09 (+0.26%)

IMMU Immunomedics
$34.17 /

+0.09 (+0.26%)

Hot Stocks
Immunomedics CEO Semerjian steps down for 'logistical obstacles' » 16:10
05/27/20
05/27
16:10
05/27/20
16:10
IMMU

Immunomedics

$34.10 /

+0.02 (+0.06%)

Immunomedics announces…

Immunomedics announces that Harout Semerjian has decided to step down from his role as President and Chief Executive Officer. "This decision, which is effective immediately, is precipitated by the unfortunate significant logistical obstacles presented by the COVID-19 pandemic, including Mr. Semerjian's ability to fully assume his duties as CEO. Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics, will continue to support the Company in an executive leadership role going forward," the company said in a statement. Immunomedics is not expecting to initiate a CEO search "until the global COVID-19 situation is stabilized."

ShowHide Related Items >><<
IMMU Immunomedics
$34.10 /

+0.02 (+0.06%)

IMMU Immunomedics
$34.10 /

+0.02 (+0.06%)

05/06/20 Piper Sandler
Immunomedics well positioned to execute on Trodelvy launch, says Piper Sandler
05/05/20 Barclays
Immunomedics initiated with an Overweight, $40 target at Barclays
05/04/20 Barclays
Immunomedics initiated with an Overweight at Barclays
04/24/20
Fly Intel: Top five analyst upgrades
IMMU Immunomedics
$34.10 /

+0.02 (+0.06%)

IMMU Immunomedics
$34.10 /

+0.02 (+0.06%)

IMMU Immunomedics
$34.10 /

+0.02 (+0.06%)

IMMU Immunomedics
$34.10 /

+0.02 (+0.06%)

Over a week ago
Upgrade
Ipsen upgraded to Neutral on Cabometyx potential at JPMorgan » 06:39
05/18/20
05/18
06:39
05/18/20
06:39
IPSEY

Ipsen

$0.00 /

+ (+0.00%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser upgraded Ipsen to Neutral from Underweight with a price target of EUR 70, up from EUR 65. The market appropriately values the potential for Cabometyx in renal cell carcinoma, suggesting limited downside from current share levels, Vosser tells investors in a research note. However, while there could be upside from Cabometyx in hepatocellular carcinoma, it is not sufficient to drive Ipsen to a position of sustainable growth, adds the analyst.

ShowHide Related Items >><<
IPSEY Ipsen
$0.00 /

+ (+0.00%)

IPSEY Ipsen
$0.00 /

+ (+0.00%)

05/18/20 JPMorgan
Ipsen upgraded to Neutral from Underweight at JPMorgan
04/23/20 Oddo BHF
Ipsen upgraded to Buy from Neutral at Oddo BHF
04/22/20 UBS
Ipsen price target raised to EUR 99 from EUR 90 at UBS
04/20/20 Barclays
Ipsen price target lowered to EUR 62 from EUR 68 at Barclays
IPSEY Ipsen
$0.00 /

+ (+0.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.